Overview
Genicular nerve ablation (GNA)—often performed as radiofrequency ablation (RFA) of the superior medial, superior lateral and inferior medial genicular nerves—is a minimally invasive option for chronic knee osteoarthritis (OA) pain when conservative care fails. Yet real‑world outcomes are heterogeneous: many patients improve, but a substantial subgroup has suboptimal response. A practical way to improve patient selection is to phenotype synovial inflammation on ultrasound before the procedure.
A prospective observational study from Daradia: The Pain Clinic evaluated whether pre‑procedural ultrasound measures of synovial effusion (SE) and synovial hypertrophy (SH) predict short‑term outcomes after ultrasound‑guided GNA. In this page, we translate the paper and the Journal Club discussion into a clinic‑ready workflow you can adopt immediately.
Key Takeaways (What to Remember)
- GNA improves pain and function at 4 weeks on average (NRS and WOMAC both improved significantly).
- Synovial hypertrophy (SH) is the stronger independent predictor of response (adjusted OR ≈ 8.75 for mild/none vs moderate/severe).
- Synovial effusion (SE) correlates with magnitude of improvement (minimal effusion → larger NRS/WOMAC reductions) but is not an independent predictor after adjustment.
- Mechanism‑based selection (inflammatory phenotyping) is more actionable than relying only on radiographic KL grading.
- High inflammatory burden (marked effusion and/or moderate–severe hypertrophy) suggests optimizing anti‑inflammatory/regenerative strategy first, then reconsidering GNA.
Why Does Genicular Nerve Ablation Work for Some Patients but Not Others?
Knee OA pain is not a single mechanism. A patient can have predominantly neurogenic nociceptive drive from periarticular structures, or predominantly inflammatory/cytokine‑driven pain from active synovitis, or a mixed picture with sensitization. Denervation targets neural transmission—so when pain is primarily inflammatory, the response to denervation may be limited. Ultrasound provides a rapid point‑of‑care window into this biology.
Study Snapshot: Ultrasound Predictors of GNA Response
Design: prospective observational cohort, single center (tertiary interventional pain clinic).
Population: 24 patients, age 40–80, KL grade ≥ II, chronic knee pain >3 months, NRS ≥4, failed conservative therapy.
Intervention: ultrasound‑guided GNA (SMGN + IMGN for all; SLGN in selected cases), RF lesioning 80°C for 90 seconds; local anesthetic post‑lesion.
Outcomes: NRS and WOMAC at baseline and 4 weeks; responder = ≥50% reduction in NRS.
Results That Change Clinical Practice
Overall improvement at 4 weeks (mean):
• NRS: 6.75 → 3.88 (mean change −2.87)
• WOMAC: 38.5 → 15.7 (mean change −22.8)
• Responder rate: 50%
How effusion influenced improvement: minimal effusion (<2 mm) had larger NRS and WOMAC reductions than >5 mm effusion.
How hypertrophy influenced success probability: mild/none hypertrophy (grades 0–1) had markedly higher responder rates than moderate/severe (grades 2–3).
Ultrasound Grading You Can Use in Clinic
The paper used point‑of‑care ultrasound focused on the suprapatellar pouch and applied structured grading for both parameters.
A) Synovial Hypertrophy (SH) – Modified OMERACT (Grades 0–3)
| Grade | Practical description (what you see) |
| 0 (Normal) | No detectable synovial thickening; minimal/absent tissue between capsule and bone. |
| 1 (Mild) | Minimal thickening without prominent bulging; smooth contours. |
| 2 (Moderate) | Noticeable bulging over femoral bone; irregular contours; increased thickness/echogenicity. |
| 3 (Severe) | Marked bulging with lobulated irregular synovium; extensive proliferation; heterogeneous echogenicity. |
B) Synovial Effusion (SE) – Suprapatellar recess thickness
| Grade | Thickness (max) and interpretation |
| 0 (Absent) | No effusion. |
| 1 (Minimal) | <2 mm fluid layer. |
| 2 (Moderate) | 2–5 mm fluid layer. |
| 3 (Marked) | >5 mm fluid layer; distension/complex echoes may be present. |
Clinical Algorithm: Ultrasound Phenotyping → Better GNA Selection
Use this as a pre‑procedure checklist (fast, clinic‑friendly):
- Step 1 — Confirm indication: chronic knee OA pain (NRS ≥4), failed conservative care, patient not ready/eligible for surgery.
- Step 2 — Ultrasound screen (suprapatellar pouch + medial joint line): grade SE and SH.
- Step 3 — Classify phenotype:
- Phenotype guidance:
- Low inflammatory phenotype: SE grade 0–1 AND SH grade 0–1 → best candidates for GNA.
- Mixed phenotype: SE grade 2–3 with SH 0–1 OR SH 2–3 with low effusion → counsel about lower success; consider optimization.
- High inflammatory/chronic synovitis phenotype: SH 2–3 (± SE 2–3) → prioritize anti‑inflammatory or regenerative strategy first; consider delaying GNA.
- Optimization options commonly discussed in Journal Club (choose per patient context):
- • Treat active synovitis/effusion: aspiration + intra‑articular steroid where appropriate; structured NSAID/anti‑inflammatory plan.
- • Regenerative/biologic approach where appropriate: PRP or growth factor concentrate (GFC) (institutional protocols vary).
- • Re‑scan after inflammatory control; proceed to GNA when phenotype shifts toward low inflammatory burden.
What is Genicular Nerve Ablation (GNA)?
GNA targets sensory branches around the knee (commonly superior medial, superior lateral, inferior medial). Under ultrasound guidance, a radiofrequency needle is placed near the accompanying genicular artery at the condyle–shaft junction. After confirming safe proximity, thermal lesioning (e.g., 80°C for ~90 seconds) is performed to reduce nociceptive transmission.
- Practical pearls from the Journal Club:
- • Use ultrasound to identify genicular arteries as reliable landmarks and maintain probe position during lesioning.
- • Procedural pain can be significant; consider adequate local anesthetic, or regional/spinal techniques where appropriate and safe.
- • Superior lateral genicular nerve may be omitted when lateral pain is not a clinical contributor; tailor targets to pain map.
How to Counsel Patients (Expectation Setting)
Use patient‑friendly language and the ultrasound findings to personalize probability and expected magnitude of relief.
- Suggested counseling points:
- • If ultrasound shows minimal hypertrophy and minimal effusion, you have a higher likelihood of meaningful improvement after GNA.
- • If there is moderate–severe synovial hypertrophy, the chance of strong response is lower; we may need to reduce inflammation first.
- • GNA is typically aimed at pain relief and function; it does not “reverse” structural OA.
- • Relief may last months; recurrence can be managed with reassessment and, in selected cases, repeat procedures or adjunct biologics.
FAQ (Clinicians)
- Is effusion or hypertrophy more important?
Effusion helps estimate magnitude of improvement, but hypertrophy is a stronger independent predictor of responder status in this study.
- Should we do Doppler synovitis routinely?
Doppler may refine inflammatory phenotyping; it was not included in this study, so future validation is needed.
- Does KL grade predict GNA response?
Radiographic grade alone often correlates poorly with pain mechanisms; ultrasound inflammatory phenotyping may be more informative for selection.
- When can we proceed in grade IV OA?
GNA can be considered when surgery is not feasible; ultrasound phenotype still matters—high hypertrophy/effusion suggests lower success.
- What if pain recurs after 12–18 months?
Reassess phenotype and contributors; selected patients may benefit from repeat GNA and/or adjunct regenerative strategies.
FAQ (Patients)
- Will this procedure cure my arthritis?
No. It aims to reduce pain and improve function. Arthritis changes may still progress.
- Is ultrasound needed before GNA?
Ultrasound can help identify inflammation patterns that influence the chance of benefit and helps guide the procedure safely.
- Is it safe?
Serious adverse events are uncommon in the literature; your clinician will discuss risks based on your health and anatomy.
- Do I need bed rest after the procedure?
Usually only short activity restriction (about 24 hours). Normal daily activity is generally encouraged thereafter, with gradual rehab.
Evidence Summary (From the JMUPM Original Article)
In this prospective cohort (n=24), both pain (NRS) and function (WOMAC) improved significantly at 4 weeks. Mild/no effusion and mild/no hypertrophy were associated with better outcomes. On Firth logistic regression, synovial hypertrophy remained an independent predictor of response (adjusted OR ~8.75; P=0.007), whereas effusion showed a nonsignificant trend (OR ~0.67; P=0.47).
Call to Action (Clinic / Course / Consultation)
If you are a clinician:
• Add a 2‑minute ultrasound synovitis screen (SE + SH grading) into your standard pre‑GNA assessment.
• Use the phenotype‑based counseling script above to improve patient expectations and satisfaction.
• Consider collecting outcome data (NRS, WOMAC) to build your own validation dataset.
If you are a patient:
• Discuss ultrasound‑based inflammatory phenotyping with your pain physician before scheduling GNA.
• Ask whether controlling effusion/synovitis first could improve your chances of benefit.
READ AT ACADEMIA
